Mattoo et al carried out an open label, multicenter, randomized, cross-over study comparing insulin lispro Mix25 [25% short-acting lispro/75% intermediate-acting lispro protamine] and
human insulin 30/70 [30% short-acting soluble
human insulin/70% intermediate acting NPH]) , in participants with type 2 diabetes, who chose to fast during Ramadan.
The global
human insulin market has a fragmented structure with large number of companies operating in the market.
1c] was similar between patients taking VIAject and those taking regular
human insulin before meals but hypoglycemic event rates were significantly reduced with VIAject (0.
Insulin analogues are synthetic molecules that do not occur naturally, whereas
human insulin matches the insulin that the human body manufactures itself.
Another interesting point from this study is that a combination of commercial assays can be used to estimate the concentrations of these insulin analogs in the presence of
human insulin.
It appeared more similar to natural
human insulin than that taken from pigs and cattle.
Insulin lispro taken shortly before meals achieved better postprandial glucose levels than did regular
human insulin or insulin lispro taken after meals.
At three months old, those given cows' milk had immune systems which reacted strongly against cows' insulin and
human insulin.
Commenting on the report, an analyst from TechNavio's Healthcare team said; "The
Human Insulin market in China has recently been witnessing a significant increase in the number of corporate agreements between global and regional vendors, which increases the competition in the market.
2)
Human Insulin Analogue Rapid acting Lispro Inj, 100 IU/ml (Recombinant DNA origin) 300 IU Disposable pen with 5 needles per pen
com)-- Increasing prevalence of diabetes and upsurge in the number of lifestyle-related conditions such as obesity are augmenting the growth of the global
human insulin market.
BfArM (Bundesinstitut fur Arzneimittel und Medizinprodukte), the German regulatory agency for drugs and medical devices, has approved the commencement of a Phase IIa clinical study of HinsBet, a fast-acting formulation of
human insulin, it was reported yesterday.
